Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
NEW YORK, March 01, 2017 -- The Madison Square Garden Company (NYSE:MSG) today made the following statement regarding next year’s Grammys.
“While we are in active negotiations to bring the Grammys back to Madison Square Garden, we want to be clear that no agreement has been reached.”
Contact: Mikyl Cordova [email protected] / (212) 631-4337
